Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
Portfolio Pulse from
Wall Street analysts have set a consensus price target for Arcutis Biotherapeutics (ARQT), indicating a potential 70.3% upside. Despite skepticism about the effectiveness of price targets, positive earnings estimate revisions suggest a possible near-term stock price increase.
November 11, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcutis Biotherapeutics (ARQT) has a consensus price target suggesting a 70.3% upside. Positive earnings estimate revisions could support a near-term price increase.
The consensus price target for ARQT indicates a significant upside potential of 70.3%. While price targets alone are not always reliable, the upward trend in earnings estimate revisions provides a strong signal for potential near-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100